Epigenetic dysregulation plays a crucial role in cardiovascular diseases. Previously, we reported that acetyltransferase p300 (ATp300) inhibitor L002 prevents hypertensioninduced cardiac hypertrophy and fibrosis in a murine model. In this short communication, we show that treatment of hypertensive mice with ATp300-specific small molecule inhibitor L002 or C646 reverses hypertension-induced left ventricular hypertrophy, cardiac fibrosis and diastolic dysfunction, without reducing elevated blood pressures.
| INTRODUC TI ON
Cardiovascular diseases are the number one cause of all diseaserelated deaths worldwide. Sustained high blood pressure causes cardiac hypertrophy and myocardial fibrosis, leading to loss of myocardial elasticity and heart failure. 1 As there is no available therapy for regression of cardiac fibrosis, it is imperative to identify a potential druggable target and its modulators for an efficient therapy.
Epigenetics plays a key role in cellular physiology and pathology by regulating gene expression via acetylation, deacetylation, methylation, demethylation and miRNA-mediated translational regulation. 2 Acetyltransferase p300 (ATp300), a major epigenetic regulator, controls numerous human cellular activities during development and its dysregulation is associated with numerous diseases including cancers, Rubinstein Taybi syndrome and long-term memory impairment. [3] [4] [5] [6] [7] We were the first to demonstrate that extracellular matrix protein Type I collagen, major contributor in organ fibrogenesis, is epigenetically regulated by ATp300, a non-DNA binding protein with intrinsic acetyltransferase activity and different functional domains
[reviewed in 8, 9 ]. This novel study documented that elevated levels of ATp300 lead to an increased synthesis of collagen by TGF-β-activated fibroblasts/myofibroblasts. Most importantly, TGF-β, the most potent profibrogenic cytokine, fails to stimulate Type I collagen synthesis in ATp300 depleted fibroblasts even in the presence of ATp300-related CBP. These results demonstrate the essential role of ATp300 in profibrogenic signal-induced collagen synthesis [reviewed in 8, 9 ]. Following this novel report, numerous studies confirmed and established the pivotal role of ATp300 in fibrogenic signalling and pathogenesis of organ fibrosis [reviewed in 2, 9 ]. Additionally, it is apparent that collagen promoter is not addicted for CBP in p300 depleted fibroblasts as has been shown for addiction of Myc gene promoter for CBP in p300 deficient cancer cells and for p300 in
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CBP deficient cancer cells. 10 More recently, we showed that L002, a potent inhibitor of p300, prevents hypertension-induced cardiac hypertrophy and fibrogenesis. 11 In this study, we also demonstrated the effectiveness of C646 and L002 in blocking TGF-β-induced profibrogenic signalling in vitro. 11 However, it is not known whether pharmacological inhibition of ATp300 halts cardiac fibrogenesis or reverses established fibrosis more relevant to drug development and effective therapy. Here, we tested the efficacies of two ATp300
inhibitors, L002 and C646, in reversing hypertension-induced established cardiac fibrogenesis in vivo.
| MATERIAL S AND ME THODS

| Generation of hypertensive mice and posttreatment with ATp300 inhibitors C646 and L002
Eight weeks old wild-type C57BL/6 male mice were purchased from Jackson laboratory, Bar Harbor, ME and were maintained. All ( Figure 1A ). The mice were sacrificed and hearts were collected after 4 weeks. A part of the heart was fixed in formalin and used for histochemical analysis. Other half of the heart was snap frozen and stored at −80°C for biochemical analysis.
| Blood pressure measurement and echocardiography
The blood pressures on week 2 and 4 were recorded by tail-cuff method. The body weight of mice in all four groups was recorded.
After 4 weeks, trans-thoracic two-dimensional M-mode echocardiography was performed as described. and ejection fractions were determined. The mean value of at least 3-5 cardiac cycles were used to determine the measurements for each animal in hypertensive groups treated with or without ATp300 inhibitor L002 or C646. Post-mortem heart weight in all mice was recorded to analyse the ratio of heart weight to body weight.
| Masson's trichrome staining for collagen
Paraffin-embedded heart tissues from all four groups were subjected to microtome sectioning and processed for Masson's trichrome staining to detect the levels of collagen deposition in hearts.
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Photographs were taken with an Olympus DP71 camera. The extent of interstitial and perivascular fibrosis in heart sections from saline +DMSO controls (n = 6), Ang II +DMSO (n = 6), Ang II +C646 (n = 5),
and Ang II +L002 mice (n = 6) were quantified by free-hand drawing and measured the area of interstitial fibrotic areas relative to total cardiac cross section areas (interstitial fibrosis in %) or perivascular fibrotic areas relative to blood vessels areas (relative perivascular fibrosis) and analysed with ImageJ-1.52a software (NIH). The effects of ATp300 inhibitors C646 and L002 on Ang II-induced cardiomyocyte hypertrophy were determined by free-hand tracing the areas of cardiomyocytes in the non-fibrotic areas (photographs taken in 60X magnification) and measurement using ImageJ-1.52a software (NIH) in all four groups. Approximately the areas of 80-100 cardiomyocytes were measured per mouse (n = 6/group) and used for statistical analysis.
| Preparation of myocardial tissue lysates and Western blot analysis
Ventricular tissue lysates were prepared using RIPA lysis buffer 
| Cell culture, treatment and Western blot
Human cardiac fibroblasts were cultured in 10% FBS containing DMEM media. Cultures of cardiac fibroblasts in 12-well clusters were treated in triplicate with ATp300 inhibitor C646 (10 µM) (Sigma Chemicals, MO) or vehicle in the presence or absence of TGF-β2 (10 ng/ml) for 48 hours. Experiments were repeated two times. Cell lysates were prepared using RIPA lysis buffer (ThermoFisher Scientific) with protease and phosphatase inhibitors (Sigma, MO) and pooled from three wells. Equal amount of proteins was subjected to Western blot using p53 (Santa Cruz
Biotech.) and Actin (Abcam) antibodies.
| Statistical analysis
Data are presented as Mean ± SEM. The significance of differences between controls and experimental groups was estimated by t test or two-way ANOVA and a value of P < 0.05 by Student t test was considered statistically significant. Statistical analyses were performed with GraphPad Prism (GraphPad Software Inc, San Diego, CA).
| RE SULTS AND D ISCUSS I ON
Pathological matrix remodelling and loss of contractility in the heart is the major cause of cardiovascular disease-related deaths.
There is no effective therapy to halt or reverse established cardiac fibrogenesis. Here, we examined the effectiveness of two small molecule inhibitors of ATp300, L002 and C646 in reversing hypertension-induced cardiac hypertrophy and fibrosis by treatment of mice after inducing hypertension for two weeks. The present approach is significant as reversal of cardiac hypertrophy and fibrosis is more relevant for developing newer epigenetic therapies targeting ATp300. We began our assessment by measuring blood pressure after 2 weeks of Ang II infusion. As expected, Ang II infusion induced a hypertensive response in all the three groups F I G U R E 2 ATp300 inhibitors effectively reverse Angiotensin II-mediated hypertension-induced myofibroblast differentiation and cardiac fibrosis. Batches of Angiotensin II-infused mice were post-treated with either DMSO (Group 2; n = 6); or C646 (Group 3, n = 5); or L002 (Group 4; n = 6). Saline-infused mice were treated with DMSO (control) (Group 1; n = 6) as described in Figure 1A legend. After 4 wk, the hearts were collected and processed for immunohistochemical analysis. Masson's trichrome staining for perivascular and interstitial collagen deposition (A); Quantification of interstitial and perivascular fibrotic areas using ImageJ 1.52a software as described under methods (B). *P < 0.05; **P < 0.01; ***P < 0.005. Effect of C646 and L002 on hypertension-induced α-SMA expression and the levels of Ac-H3K9 in myocardial tissue lysates pooled from six hearts in each group (n = 6) and subjected to Western blot analysis using antibodies against α-SMA, Ac-H3K9 and α-Tubulin (C) F I G U R E 1 Post-treatment of hypertensive mice with ATp300 inhibitors reverse hypertension-induced ventricular wall thickness. Hypertension was induced by minipump-mediated infusion of Angiotensin II in wild-type mice. Minipump-mediated saline infused mice were used as normotensive control. Angiotensin II-induced hypertensive mice were treated with either DMSO (Group 2; n = 6); or C646 (Group 3, n = 6); or L002 (Group 4; n = 6) for 2-wk on every 3rd day by intraperitoneal injection after 2 wk of saline or Angiotensin II minipump implantation. Saline-infused mice were treated with DMSO (control) (Group 1; n = 6) (A). Blood pressures were recorded on weeks 2 and 4 (B) using tail-cuff method. Echocardiogram was performed on week 4. Echocardiography showing images of the left ventricular wall thickness (LVWT) (C) and quantification data (D). The quantitative data of left ventricular end diastolic diameter (LVEDD) in four groups are shown in E. Heart weight to body weight are presented in F. ns, not significant; *P < 0.05; ***P < 0.005
( Figure 1A,B) . After induction of hypertension for 2 weeks, mice in groups 3 and 4 were treated with C646 and L002 by intraperitoneal injection respectively. Interestingly, co-treatment for last 2 weeks with C646 or L002 had no effect on blood pressure as high SBP were measured at the end of week 4 ( Figure 1B ). Figure S2 ). Post-mortem analysis revealed that Ang II-induced hypertension increased heart weight to body weight as expected.
However, co-treatment of mice with ATp300 inhibitors C646 or L002 for last 2 weeks had no significant effect on cardiac weight ( Figure 1F ). Figure 2C ). This observation is highly significant as firstly, it confirms that ATp300 inhibitors L002 and C646 are acting through epigenetic modifications; and secondly, differentiation of resident cardiac fibroblasts or endothelial cells to myofibroblasts and increased synthesis and secretion of collagen by myofibroblasts are major events in the progression of fibrogenesis [reviewed in 2, 12 ].
The reversal of myofibroblast differentiation or conversion of excessive collagen producing myofibroblasts to fibroblasts or collagenase producing senescent myofibroblasts 12, 13 by ATp300 inhibitors is highly significant in the context of therapy.
Additionally, we have previously shown that treatment of human cardiac fibroblasts with ATp300 inhibitor C646 blocks TGF-β-induced collagen synthesis. 11 Interestingly, the levels of p53 are significantly elevated in C646-treated cardiac fibroblasts ( Figure   S3 ). Previously, we have demonstrated that p53 is a negative reg- 
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